SecBot SecBot
8-K ·Filed Aug 13, 2026

KPTI

Karyopharm Therapeutics Inc.
BEARISH
Impact 8/10
Horizondays Processed3mo ago SEC0001193125-26-347897
8-K Item 2.02: Earnings release
Actionable Insight ▼ Bearish

The imminent cash runway and September 10 debt payment create a binary near-term catalyst: either the company secures financing or strategic alternatives (including potential sale) before the liquidity covenant breach, or it faces default. The August sNDA submission for myelofibrosis is a positive pipeline catalyst but does not resolve the near-term liquidity crisis. Traders should watch for financing announcements, potential equity dilution, or a strategic transaction in the coming weeks.

DirectionBearish
Confidencehigh
Horizondays

How the stock moved after the report

BEARISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$1.99
T+0 close · Aug 13, 2026 · via day close
Latest settled
−97.24%
T+60 · $0.0549
Vs SPY
−91.77%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 13 $1.99entry
  2. T+1 · 3mo ago +1.51%α +1.71% · $2.02
  3. T+5 · 3mo ago −8.54%α −6.58% · $1.82
  4. T+20 · 2mo ago −19.10%α −17.35% · $1.61
  5. T+60 · 11d ago −97.24%α −91.77% · $0.0549

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Karyopharm reported Q2 2026 total revenue of $33.4M, down 12% YoY from $37.9M, driven by a $5.6M decline in license and other revenue. The company reaffirmed full-year 2026 guidance of $130M-$150M total revenue and remains on track for an August sNDA submission for selinexor in myelofibrosis under the Accelerated Approval pathway. Critically, the company disclosed it expects cash to fund operations only into September 2026 and is actively evaluating financing or strategic alternatives, with a $15.8M debt payment due September 10 that could trigger a liquidity covenant default.

Key Financial Metrics

EPS
−$2.32
est −$1.53 · -51.6%
Revenue
$33.4M
est $32.2M · +3.8% · -11.8% YoY
Rating
miss
Guidance
$130M-$150M
maintained
Gross Margin
96.75%

Key Facts

  • Total revenue declined 12% YoY to $33.4M from $37.9M
  • Net loss widened to $67.0M from $37.3M YoY, driven by $32.1M in non-cash other expense
  • Cash, cash equivalents and investments totaled $65.4M as of June 30, 2026
  • Company expects existing liquidity to fund operations only into September 2026
  • $15.8M principal payment due September 10, 2026; payment without financing would breach $10M minimum liquidity covenant
  • Company is actively evaluating financing opportunities and strategic alternatives with Centerview Partners
  • Phase 3 XPORT-EC-042 endometrial cancer trial did not meet its primary endpoint of PFS
  • Planned August sNDA submission for selinexor in myelofibrosis under Accelerated Approval remains on track
  • Full-year 2026 total revenue guidance reaffirmed at $130M-$150M

Financial Impact

Cash runway extends only into September 2026 with a $15.8M debt payment due September 10 that risks a liquidity covenant breach; net loss of $67.0M in Q2 vs $37.3M in Q2 2025

revenuenet losscash positiondebt covenant compliance

Risk Factors

  • Liquidity covenant breach on September 10 if no financing or waiver obtained
  • Potential for highly dilutive equity financing given $48M market cap
  • Endometrial cancer trial failure removes a key pipeline value driver
  • Going concern risk if financing not secured

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
75% bullish (12 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-347897
Document: kpti-20260813.htm0001193125-26-347897
Document: 0001193125-26-347897-index-headers.html0001193125-26-347897
Document: 0001193125-26-347897-index.html0001193125-26-347897
Document: 0001193125-26-347897.txt0001193125-26-347897
8-K Data (Synthetic)0001193125-26-347897

US Market Status

Market Closed · Opens in 7h 48m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 13, 2026